[Treatment of chronic hepatitis C--new drugs, new hope].
The next generation of anti-HCV therapeutics agents will fall into new interferons and interferon inducers, alternatives to ribavirin, specific HCV inhibitors and immune therapies. According to HCV variability, the clinical success of HCV-targeted drugs will depend on their ability to suppress all viral variants as well as prevent the emergence of resistant viruses. Examination of these properties are limited in the absence of convenient animal model of HCV infection and limited possibilities studies on HCV replicons. The NS3-4A serine protease and the NS5B RNA polymerase have emerged as popular target for antiviral intervention. Blockage ofNS3 activity is expected to inhibit HCV replication by direct suppression of viral protein production and restoration of host responsiveness to IFN. The experience with synthetic agonists of Toll-like receptors 7 and 9 have begun to show their potential in controlling HCV infection. The new anti-HCV agents have progressed through early-phase clinical trials. Based on HCV infection history it seems that IFN will be the gold standard of the therapy and new agents probably will administer in combination with IFN.